Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome

NCT00885833 is registered in ClinicalTrials.gov with The Korean Society of Pediatric Hematology Oncology as lead sponsor.

NCT NCT00885833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00885833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome
Lead sponsor
The Korean Society of Pediatric Hematology Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2007
Completion date
March 31, 2012
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

wiskott-aldrich syndrome